YOLFTbeta
Summit Therapeutics PLC

Summit Therapeutics PLC

SMMT · NASDAQ · Healthcare / Biotechnology

14.15USD-0.92 (-6.14%)

Price History

Full chart

Market Stats

Previous Close15.08
Open15.20
Day Range14.06 – 15.20
52-Week Range12.07 – 29.23
Volume5.48M
Market Cap14.26B
P/E (TTM)0.00
Forward P/E3.72
EPS-1.06
Dividend Yield0.00%
Beta-1.52
50-Day Avg16.41
200-Day Avg16.15

About

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Robert W. Duggan
  • Employees265
  • Headquarters601 Brickell Key Drive, Miami, FL, United States, 33131, USA
  • Websitehttps://www.smmttx.com

Leadership

  • Mr. Robert W. DugganCo-CEO & Executive Chairman · b. 1944
  • Dr. Mahkam Zanganeh D.D.S., M.B.A.Co-CEO, President & Director · b. 1970
  • Mr. Manmeet Singh Soni CPACOO, CFO & Director · b. 1978
  • Prof. Kay Elizabeth Davies DBE, FRS CBECo-Founder, Chairman of Scientific Advisory Board and Scientific Advisor · b. 1951
  • Mr. Bhaskar AnandChief Accounting Officer & Head of Finance · b. 1978
  • Mr. Nathan LiaBraatenSenior Director of Investor Relations
  • Dr. Elaine Carla Stracker J.D., Ph.D.Chief Legal Officer · b. 1961
  • Mr. Dave Gancarz CPAChief Business & Strategy Officer
  • Dr. Wang Clow Fong ScDChief Biometrics Officer · b. 1958
  • Dr. Urte Gayko Ph.D.Chief Regulatory, Quality & Pharmacovigilance Officer · b. 1971

Financials

Income Statement

Currency: GBP2003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.82K212.76K947.89K2.03M6.03M266.64K301.94K738.80K1.12M1.90M1.84M1.89M1.28M2.38M14.17M57.09M43.01M628.88K1.81M705.00K000
Growth (%)-+11564.53%+345.52%+113.95%+197.09%-95.57%+13.24%+144.68%+51.09%+69.76%-2.69%+2.39%-32.15%+85.48%+496.30%+302.94%-24.66%-98.54%+187.66%-61.03%-100.00%--
Cost of Revenue1.82K169.46K415.93K596.30K3.23M5.76K2.32M434.76K190.33K93.51K24.72K050.96K61.65K97.67K24.92K199.50K--2.51M2.05M15.01M108.36K
Gross Profit43.31K43.30K531.96K1.43M117.34K260.87K-2.13M304.04K1.12M1.90M1.84M1.89M1.28M2.38M14.17M56.39M43.01M628.88K1.81M705.00K-2.05M-15.01M-108.36K
Gross Margin2374.21%20.35%56.12%70.61%1.95%97.84%-706.85%41.15%100.00%100.00%100.00%100.00%100.00%100.00%100.00%98.77%100.00%100.00%100.00%100.00%---
Operating Expense87.09K580.30K3.74M10.03M23.52M19.46M7.07M9.69M5.83M6.47M8.55M14.12M21.63M27.23M40.00M51.00M27.86M72.27M88.00M72.79M607.60M210.99M1.09B
Operating Income-43.79K-537.00K-3.21M-8.60M-23.41M-19.20M-9.20M-9.38M-4.71M-4.58M-6.71M-12.23M-20.35M-24.85M-25.83M5.39M15.16M-71.65M-86.19M-72.09M-609.65M-226.00M-1.09B
Operating Margin-2400.60%-252.40%-338.96%-423.82%-388.46%-7198.87%-3047.57%-1270.03%-422.30%-241.53%-363.83%-647.93%-1588.29%-1046.00%-182.31%9.44%35.24%-11392.73%-4764.29%-10225.39%---
EBITDA-66.77K-527.00K-2.97M-6.13M-18.58M-16.03M-5.41M-8.64M-1.60M-3.79M-6.68M-12.20M-20.30M-24.79M-26.17M11.65M15.68M-36.27M-83.73M-62.09M-88.48M-210.88M-1.08B
EBITDA Margin-3660.47%-247.70%-313.54%-302.47%-308.43%-6010.20%-1790.36%-1170.14%-143.64%-199.91%-362.38%-646.24%-1584.64%-1043.53%-184.72%20.42%36.45%-5766.84%-4628.58%-8807.66%---
Net Income-41.96K-86.61K-1.90M-5.92M-20.13M-32.29M-5.34M-7.42M-4.23M-4.22M-6.09M-11.38M-20.14M-21.37M-20.16M10.87M4.99M-38.53M-86.15M-78.78M-614.93M-221.31M-1.08B
Net Income Margin-2300.60%-40.71%-200.02%-292.11%-334.07%-12109.63%-1769.24%-1004.60%-378.97%-222.96%-330.42%-602.97%-1571.98%-899.45%-142.28%19.04%11.61%-6127.56%-4762.13%-11174.75%---
R&D46.50K504.60K1.83M5.79M15.34M7.38M3.68M2.24M3.08M4.73M6.61M10.42M16.86M18.95M28.98M49.07M39.18M38.96M85.35M52.00M580.39M165.78M537.67M
R&D as % of Total Revenue2549.34%237.17%193.27%285.50%254.52%2767.04%1218.10%303.41%275.99%249.66%358.51%551.75%1315.85%797.64%204.54%85.95%91.10%6194.65%4718.19%7375.74%---
Interest Expense1.82K404.81K11.77K11.77K75.56K116.74K107.04K6.33K4.71K1.58M14.85K448.00K351.06K1.08M1.65M620.00K41.75K255.00K281.00K5.32M20.98M10.88M0
Interest Expense % of Total Revenue100.03%190.27%1.24%0.58%1.25%43.78%35.45%0.86%0.42%83.52%0.81%23.73%27.41%45.33%11.63%1.09%0.10%40.55%15.53%754.61%---

Balance Sheet

Currency: GBP2003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets145.96K26.88M25.87M46.44M69.38M20.09M18.38M8.06M6.12M6.91M12.03M29.22M35.71M46.98M76.38M79.53M75.46M75.29M84.04M664.17M202.95M435.56M751.18M
Total Liabilities3.65K350.21K2.49M6.33M15.30M7.77M5.15M2.24M2.34M2.41M4.18M9.69M5.62M51.35M62.40M23.74M14.34M16.93M22.30M537.51M125.26M46.81M92.32M
Total Equity142.31K26.53M23.38M40.11M54.08M12.33M13.22M5.82M3.78M4.50M7.85M19.53M30.10M-4.37M13.98M55.79M61.12M58.36M61.74M126.65M77.69M388.75M658.86M
Cash145.96K26.66M1.86M35.87M20.06M3.92M9.72M5.14M3.26M5.34M3.35M16.97M23.22M35.08M28.45M35.23M49.96M48.78M53.22M348.61M71.42M104.86M225.27M
Total Debt-1.35M1.35M1.30M2.80M1.90M------5.09M5.09M18.03M0699.64K341.55K2.06M518.76M106.10M7.22M20.89M
Net Debt-145.96K-26.66M-505.19K-34.57M-17.26M-2.02M-9.72M-5.14M-3.26M-5.34M-3.35M-16.97M-23.22M-35.08M-28.45M-35.23M-49.26M-48.44M-51.15M170.16M34.67M-97.64M-204.38M

Cash Flow

Currency: GBP2003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-64.97K29.74K-931.84K-5.96M-16.13M-14.72M-2.65M-4.34M-3.80M-5.03M-9.68M-16.59M-24.47M15.18M-20.58M-35.11M-26.66M-35.34M-53.81M-41.58M-76.76M-142.11M-322.93M
Investing Cash Flow--6.63K-1.40M-2.32M-1.52M-1.22M-115.03K-170.91K-172.73K-102.67K105.57K24.11K-51.27K-100.00K-7.42M-331.00K-121.00K-309.23K-226.83K-624.00K-587.77M-205.34M-174.31M
Financing Cash Flow137.01K26.47M1.35M19.38M1.33M5.31M8.14M25.32K2.13M7.19M7.35M30.48M31.53M516.23K19.47M44.51M33.11M37.13M57.76M620.24M86.51M381.23M617.53M
Capital Expenditure11.30K13.18K2.45M3.37M3.86M1.65M140.59K193.06K190.01K120.04K77.53K52.73K94.00K110.00K678.01K164.00K265.33K309.23K226.83K624.00K128.00K139.00K657.00K
Free Cash Flow-64.98K43.30K-4.08M-9.33M-19.99M-16.37M-2.79M-4.53M-3.99M-5.15M-9.76M-16.64M-24.56M15.07M-21.26M-35.27M-15.83M-35.65M-54.03M-42.21M-76.89M-142.25M-323.59M
Dividends Paid------------0000-------
FCF to OCF100.00%145.60%437.74%156.58%123.96%111.23%105.31%104.45%105.00%102.38%100.80%100.32%100.38%99.28%103.29%100.47%59.37%100.88%100.42%101.50%100.17%100.10%100.20%
Dividend Paid to FCF------------0.00%0.00%0.00%0.00%-------

Earnings

Report DateJun 11, 2015Aug 27, 2015Dec 17, 2015Jun 2, 2016Sep 8, 2016Dec 15, 2016Mar 29, 2017Jun 14, 2017Aug 31, 2017Dec 6, 2017Jun 5, 2018Sep 20, 2018Dec 11, 2018Mar 27, 2019Jun 26, 2019Dec 17, 2019Apr 30, 2020Sep 29, 2020Nov 16, 2020Mar 17, 2021May 17, 2021Aug 11, 2021Nov 15, 2021Mar 17, 2022May 11, 2022Aug 11, 2022Nov 9, 2022Mar 9, 2023May 11, 2023Aug 9, 2023Nov 7, 2023Feb 20, 2024May 1, 2024Aug 6, 2024Oct 30, 2024Feb 24, 2025Apr 29, 2025Aug 11, 2025Oct 20, 2025Feb 23, 2026May 7, 2026Jul 23, 2026Oct 19, 2026Nov 4, 2026
EPS Estimate-0.06-0.07-0.10-0.27-0.10-0.02--0.140.25-0.10-0.10-0.30-0.12-0.24-0.16-0.40-0.03-0.06-0.01-0.16-0.21-0.13-0.21-0.28-0.22-0.17-0.14-0.07-1.43---0.05-0.05-0.05-0.05-0.06-0.07-0.09-0.04-0.01-0.12-0.26-0.28-0.28
EPS Actual-0.06-0.07-0.08-0.45-0.50-0.40-0.50-0.400.85-0.15-0.401.83-0.50-0.35-0.20-0.22-0.03-0.18-1.24-0.13-1.05-0.19-0.15-0.28-0.22-0.17-0.14-0.07-1.43-0.02-0.03-0.04-0.05-0.07-0.06-0.06-0.07-0.12-0.23-0.21-0.18-0.28-0.31-0.26
Surprise0.00%0.00%20.00%-66.67%-400.00%-1900.00%--185.71%240.00%-50.00%-300.00%710.00%-316.67%-45.83%-25.00%45.00%0.00%-200.00%-12300.00%18.75%-400.00%-46.15%28.57%0.00%0.00%0.00%0.00%0.00%0.00%--20.00%0.00%-40.00%-20.00%0.00%0.73%-33.33%-475.00%-2000.00%-45.19%-7.69%-10.71%7.14%
TimingPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-market---------Pre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap14.26B
Enterprise Value13.66B
Trailing P/E0.00
Forward P/E3.72
PEG Ratio0.00
Price / Sales3891.31
Price / Book25.27
EPS-1.06
Book Value0.706
Revenue (TTM)0
Gross Profit (TTM)705.00K
EBITDA-855.03M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-220.01%
Return on Assets-111.99%
Shares Outstanding799.76M
Shares Float154.30M
Beta-1.52
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 17 analystsTarget 29.73
  • Strong Buy
    10
  • Buy
    1
  • Hold
    6

Ownership Breakdown

Institutions
17.03%
Insiders
80.68%
Retail / Other
2.29%

Top Institutional Holders

  • Baker Bros Advisors LP
    32.79M4.10%
  • FMR Inc
    10.04M1.26%
  • State Street Corp
    9.54M1.19%
  • BlackRock Inc
    9.53M1.19%
  • Vanguard Capital Management, LLC
    5.73M0.72%
  • UBS Group AG
    5.23M0.65%
  • Vanguard Portfolio Management, LLC
    5.04M0.63%
  • The Goldman Sachs Group Inc
    4.51M0.56%
  • T. Rowe Price Associates, Inc.
    3.89M0.49%
  • Point72 Asset Management, L.P.
    3.70M0.46%
  • Geode Capital Management, LLC
    3.43M0.43%
  • Millennium Management LLC
    2.35M0.29%
  • Adage Capital Partners Gp LLC
    1.99M0.25%
  • Balyasny Asset Management LLC
    1.90M0.24%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    5.12M0.64%
  • State Street® SPDR® S&P® Biotech ETF
    3.90M0.49%
  • Vanguard Small Cap Index
    3.59M0.45%
  • T. Rowe Price Health Sciences
    3.35M0.42%
  • Vanguard MStar Small Cap Value Index
    2.34M0.29%
  • Fidelity Growth Company Fund
    2.05M0.26%